A Model of Basement Membrane-Associated Gene Signature Predicts Liver Hepatocellular Carcinoma Response to Immune Checkpoint Inhibitors

Figure 6

The BMRG risk score predicts immunotherapeutic benefits. (a) Association of BMRG risk scores with immune checkpoints. (b) Association of four BMRGs with eleven immune checkpoints. (c, d) The proportion of patients with clinical response to anti-PD1 and anti-CTLA4 immunotherapy in the low- or high-BMRG-risk group. (e) Differences in immune escape score between the high- and low-risk groups. (f) Differences in TIDE scores between the high- and low-risk groups.

(a)

(b)

(c)

(d)

(e)

(f)